Biotech Stocks Under Scanner -- Celldex Therapeutics, Achillion Pharma, Vertex Pharma, and Concordia

Friday, February 17, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, February 17, 2017 /PRNewswire/ -- has aligned four equities in the Biotech industry for

assessment this morning, and they are Celldex Therapeutics Inc. (NASDAQ: CLDX), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Concordia International Corp. (NASDAQ: CXRX). These companies belong to the
Healthcare sector which was slightly lower in late trade on Thursday, February 16th, 2017, with the NYSE Health Care Index slipping about 0.1%, while shares of health care companies in the S&P 500 were down 0.2% as a group. You can access our complimentary research reports on these stocks now at:

Celldex Therapeutics  

Hampton, New Jersey headquartered Celldex Therapeutics Inc.'s shares saw a decline of 1.12%, finishing Thursday's trading session at $3.52. A total volume of 1.28 million shares was traded. In the last one month, the stock has advanced 0.57%. The Company's shares are trading below their 50-day moving average by 1.92%. Moreover, shares of Celldex Therapeutics, which develops, manufactures, and commercializes novel therapeutics for human health care, have a Relative Strength Index (RSI) of 51.86. Visit us today and download your complete report on CLDX for free at:

Achillion Pharma  

On Thursday, shares in New Haven, Connecticut headquartered Achillion Pharmaceuticals Inc. recorded a trading volume of 3.37 million shares, which was above their three months average volume of 1.69 million shares. The stock ended the session 9.34% lower at $4.27. The Company's shares have gained 2.89% in the last one month and 3.39% on an YTD basis. The stock is trading 1.22% above its 50-day moving average. Furthermore, shares of Achillion Pharma, which discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the US and internationally, have an RSI of 49.84.

On December 28th, 2016, Achillion Pharmaceuticals announced that it has received a $15 million milestone payment from Janssen Research & Development, LLC., part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), related to enrollment in the OMEGA-1 Phase-2b global, clinical trial of JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and AL-335 in patients with treatment-naive chronic hepatitis C virus infection without cirrhosis.

On February 02nd, 2017, research firm Ladenburg Thalmann initiated a 'Buy' rating on the Company's stock, with a target price of $10 per share. The complimentary research report on ACHN can be accessed at:

Vertex Pharma  

Shares in Boston, Massachusetts headquartered Vertex Pharmaceuticals Inc. closed at $87.70, down 1.87% from the last trading session. The stock recorded a trading volume of 1.32 million shares. The Company's shares have gained 6.28% in the last one month and 19.04% since the start of this year. The stock is trading 8.43% and 0.53% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Vertex Pharma, which engages in discovering, developing, manufacturing, and commercializing medicines for serious diseases, have an RSI of 58.82.

On January 26th, 2017, Vertex reported total revenues of $458.71 million for Q4 2016 compared to revenue of $417.94 million for Q4 2015. The Company's GAAP net income was $32.9 million, or $0.13 per diluted share, for Q4 2016 compared to GAAP net loss of $(73.7) million, or $(0.30) per diluted share, for Q4 2015. As of December 31st, 2016, Vertex had $1.43 billion in cash, cash equivalents, and marketable securities. On January 11th, 2017, Vertex entered into a licensing agreement with Merck KGaA, Darmstadt, Germany for four clinical and pre-clinical oncology programs. Under the agreement, Vertex expects to receive $230 million in up-front payments in Q1 2017.

On January 26th, 2017, research firm Stifel reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $108 a share to $100 a share. Register for free on and download the PDF research report on VRTX at:


At the closing bell yesterday, shares in Oakville, Canada headquartered Concordia International Corp. ended 3.31% lower at $2.63 with a total trading volume of 921,092 shares. The stock has advanced 26.44% in the last one month and 24.06% on an YTD basis. The Company's shares are trading above their 50-day moving average by 16.17%. Furthermore, shares of Concordia International, which owns a portfolio of branded and generic prescription products in the US and internationally, have an RSI of 54.91.

On February 01st, 2017, Concordia International announced that it has paid the second and final installment of its earn-out to Cinven1 relating to Concordia's October 2015 acquisition of Amdipharm Mercury Limited. The Company stated that the latest payment of £72 million, plus interest of approximately £1.5 million, was paid with cash on hand. Get free access to your research report on CXRX at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44-33- 808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store